Durgical
EN
Open the app

How monoclonal antibodies are made: hybridomas to fully human

  • Topic

Monoclonal antibodies are one antibody copied endlessly; they began as mouse proteins and were rebuilt, step by step, to look human so patients tolerate them.

Updated

What it is

A monoclonal antibody comes from a single B-cell clone and binds a single epitope. The first method, the hybridoma, fused antibody-making mouse B cells with immortal myeloma cells. Because mouse antibodies trigger an immune response in patients, they were engineered into chimeric, humanised and fully human forms, and later into fragments, conjugates and bispecific molecules. The structure is encoded in the drug name and explains side effects such as anti-drug antibodies.

Key facts

  • The hybridoma technique was described in 1975 and earned a Nobel Prize in 1984.
  • Antibody names traditionally contain a target infix (for example -li- for immune system, -tu- for tumour) before the stem.
  • Newer international non-proprietary names use other stems for new antibodies, so the classic -mab rules apply mainly to older drugs.
  • Fc engineering can increase or remove effector functions (ADCC, complement) or extend half-life.

Step by step

  1. A mouse is immunised with the target antigen.
  2. Spleen B cells are fused with myeloma cells that cannot make an enzyme needed to survive in a selective (HAT) medium.
  3. Only fused hybridoma cells survive: the B cell supplies the enzyme, the myeloma cell immortality.
  4. Hybridoma clones are screened and the one making the desired antibody is grown indefinitely.
  5. The antibody genes are then engineered: mouse constant regions are replaced by human ones (chimeric), or only the binding loops are kept (humanised).
  6. Fully human antibodies come from phage display libraries or mice carrying human immunoglobulin genes.

Types of therapeutic antibodies

TypeStructureClassic name stemExamples
MurineEntirely mouse-omabEarly agents, now rarely used (strong anti-mouse responses)
ChimericMouse variable regions + human constant regions-ximabRituximab, infliximab
HumanisedOnly the complementarity-determining regions are mouse-zumabTrastuzumab, tocilizumab, omalizumab
Fully humanEntirely human sequence-umabAdalimumab, dupilumab
Receptor–Fc fusion proteinReceptor fragment joined to IgG Fc-ceptEtanercept, abatacept
Bispecific and conjugatesTwo specificities, or antibody plus drug or toxinVariesBlinatumomab (CD19 × CD3), trastuzumab emtansine

Clinical notes

  • Anti-drug antibodies can reduce response or cause infusion reactions, more often with chimeric agents; combining infliximab with methotrexate lowers this risk.
  • Monoclonal antibodies are also lab tools: flow cytometry, immunohistochemistry, ELISA and rapid tests all depend on them.
  • Biosimilars are near-identical copies of a reference antibody, approved after comparative studies.

Common traps

  • Fully human antibodies never induce anti-drug antibodies: they are less immunogenic, but idiotypes are new to the patient and anti-drug antibodies still occur.
  • Every antibody name follows the -ximab/-zumab/-umab rule: names given since about 2022 use new stems (-tug, -bart, -mig, -ment) that no longer encode the source species.
  • In HAT medium the myeloma cell survives and the B cell dies: unfused myeloma cells die (no salvage enzyme), unfused B cells die naturally; only hybrids live.
  • Etanercept is a monoclonal antibody: it is a receptor–Fc fusion protein (-cept), with a TNF receptor fragment, not antibody variable regions.

Test yourself

Think of the answer, then tap the question to see it.

Why do only hybridoma cells survive in HAT medium?

The myeloma partner lacks the salvage enzyme (HGPRT) and dies, unfused B cells die naturally; the hybrid gets the enzyme from the B cell and immortality from the myeloma.

A patient on a chimeric anti-TNF antibody loses response after a year. What is a likely immune reason, and how is the risk lowered?

Anti-drug antibodies against its mouse variable regions; co-prescribing methotrexate reduces their formation.

What kind of molecule is blinatumomab, and how does it kill leukaemia cells?

A bispecific T-cell engager binding CD19 on B cells and CD3 on T cells, so it brings T cells into contact to kill the B cells.

Add to my cards (3)

Elsewhere in DurgiPedia

Connections

← All of immunology

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: Monoclonal Antibodies (National Cancer Institute (NIH), 2024); Antibody (MedlinePlus, US National Library of Medicine, 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.